Our story
- About us
- Latest
- Centres
Our science
- Mission
  - Discover
  - Develop
  - Deliver
- Approaches
- Explore by
Our people
- Researchers
- Governance
- Latest
  
  Sep 10, 2024
  
  Shaping the future of dementia research: Meet the UK DRI’s newest Emerging Leaders
  
  We are pleased to announce three new UK DRI Emerging Leaders: Dr Maura Malpetti, Dr...
  Learn more Shaping the future of dementia research: Meet the UK DRI’s newest Emerging Leaders
Our partners
- Partnerships
- Initiatives
  - Dementia Trials Accelerator (DTA)
  - CURE-ND
- Latest
  
  Jan 01, 2024
  
  Why partner with the UK DRI?
  
  The UK DRI is central to a rich and connected dementia research ecosystem, and we...
  Learn more Why partner with the UK DRI?
Careers
- Join us
  - Vacancies
  - Centres
- Latest
  
  Jan 01, 2024
  
  Why join the UK DRI?
  
  By joining the UK DRI you’ll belong to a team of world-class researchers, technical specialists...
  Learn more Why join the UK DRI?
Public Information
- Information
- Dementias
- Movement conditions

Lancet Neurol

Published Jan 01, 2020

Neuromyelitis optica in patients with increased interferon alpha concentrations.

Authors

Jac Williams, Sarah McGlasson, Sarosh Irani, Darragh Duffy, Yanick Crow, David Hunt,

Read More

Abstract

PMID:31839246 | DOI:S1474-4422(19)30445-4

UK DRI Authors

Dr Darragh Duffy

Leader of the Translational Immunology unit, Institut Pasteur

Dr Darragh Duffy

Male with grey hair and round glasses

Prof Yanick Crow

Clinician scientist, University of Edinburgh

Prof Yanick Crow

Prof David Hunt

Group Leader

Investigating how innate immune activation causes damage to the microvasculature of the brain

Prof David Hunt

Paul Matthews

Prof Paul Matthews

Group Leader

Exploring neuronal vulnerability and genetic risk variants in Alzheimer’s progression

Prof Paul Matthews